Patents Assigned to COVIS PHARMA GMBH
  • Methods of reducing risk of preterm birth
    Patent number: 11730744
    Abstract: This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: August 22, 2023
    Assignee: COVIS PHARMA GMBH
    Inventors: Robert Birch, Michael J. Jozwiakowski
  • Methods of reducing risk of preterm birth
    Patent number: 11304962
    Abstract: This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: April 19, 2022
    Assignee: COVIS PHARMA GMBH
    Inventors: Robert Birch, Michael J. Jozwiakowski
  • Methods of Reducing Risk of Preterm Birth
    Publication number: 20210353644
    Abstract: This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth.
    Type: Application
    Filed: April 30, 2021
    Publication date: November 18, 2021
    Applicant: COVIS Pharma GmbH
    Inventors: Robert BIRCH, Michael J. JOZWIAKOWSKI
  • Methods of reducing risk of preterm birth
    Patent number: 11154562
    Abstract: This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: October 26, 2021
    Assignee: COVIS PHARMA GMBH
    Inventors: Robert Birch, Michael J. Jozwiakowski
  • Methods of Reducing Risk of Preterm Birth
    Publication number: 20210322444
    Abstract: This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth.
    Type: Application
    Filed: June 30, 2021
    Publication date: October 21, 2021
    Applicant: COVIS Pharma GmbH
    Inventors: Robert BIRCH, Michael J. JOZWIAKOWSKI
  • Aqueous suspensions of ciclesonide for nebulisation
    Patent number: 11052042
    Abstract: This invention relates to a method for the preparation of sterile aqueous suspensions of ciclesonide by sterilization with moist heat. The invention further relates to pharmaceutical compositions in particular to sterile aqueous suspensions of ciclesonide for administration by nebulization in the prophylaxis and/or treatment of respiratory diseases.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: July 6, 2021
    Assignee: Covis Pharma GMBH
    Inventor: Antje Brueck-Scheffler
  • Pharmaceutical aerosol product for administration by oral or nasal inhalation
    Patent number: 11007150
    Abstract: The inventive subject matter relates to a pharmaceutical aerosol product suitable for administration by oral or nasal inhalation and its use in the treatment of respiratory diseases, in particular in the treatment of children.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: May 18, 2021
    Assignee: COVIS PHARMA GMBH
    Inventors: Helgert Muller, Renate Engelstatter, Ulrich Bildmann, Andrea Bauer, Paul Mcglynn